These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
265 related articles for article (PubMed ID: 15378492)
1. Intensity-modulated radiotherapy for early-stage nasopharyngeal carcinoma: a prospective study on disease control and preservation of salivary function. Kwong DL; Pow EH; Sham JS; McMillan AS; Leung LH; Leung WK; Chua DT; Cheng AC; Wu PM; Au GK Cancer; 2004 Oct; 101(7):1584-93. PubMed ID: 15378492 [TBL] [Abstract][Full Text] [Related]
2. Initial experience using intensity-modulated radiotherapy for recurrent nasopharyngeal carcinoma. Lu TX; Mai WY; Teh BS; Zhao C; Han F; Huang Y; Deng XW; Lu LX; Huang SM; Zeng ZF; Lin CG; Lu HH; Chiu JK; Carpenter LS; Grant WH; Woo SY; Cui NJ; Butler EB Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):682-7. PubMed ID: 14967420 [TBL] [Abstract][Full Text] [Related]
3. Treatment of nasopharyngeal carcinoma with intensity-modulated radiotherapy: the Hong Kong experience. Kam MK; Teo PM; Chau RM; Cheung KY; Choi PH; Kwan WH; Leung SF; Zee B; Chan AT Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1440-50. PubMed ID: 15590175 [TBL] [Abstract][Full Text] [Related]
4. Preservation of oral health-related quality of life and salivary flow rates after inverse-planned intensity- modulated radiotherapy (IMRT) for head-and-neck cancer. Parliament MB; Scrimger RA; Anderson SG; Kurien EC; Thompson HK; Field GC; Hanson J Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):663-73. PubMed ID: 14967418 [TBL] [Abstract][Full Text] [Related]
5. [Intensity modulated radiotherapy for local-regional advanced nasopharyngeal carcinoma]. Zhao C; Han F; Lu LX; Huang SM; Lin CG; Deng XW; Lu TX; Cui NJ Ai Zheng; 2004 Nov; 23(11 Suppl):1532-7. PubMed ID: 15566674 [TBL] [Abstract][Full Text] [Related]
6. Xerostomia and quality of life after intensity-modulated radiotherapy vs. conventional radiotherapy for early-stage nasopharyngeal carcinoma: initial report on a randomized controlled clinical trial. Pow EH; Kwong DL; McMillan AS; Wong MC; Sham JS; Leung LH; Leung WK Int J Radiat Oncol Biol Phys; 2006 Nov; 66(4):981-91. PubMed ID: 17145528 [TBL] [Abstract][Full Text] [Related]
7. Dose-volume modeling of salivary function in patients with head-and-neck cancer receiving radiotherapy. Blanco AI; Chao KS; El Naqa I; Franklin GE; Zakarian K; Vicic M; Deasy JO Int J Radiat Oncol Biol Phys; 2005 Jul; 62(4):1055-69. PubMed ID: 15990009 [TBL] [Abstract][Full Text] [Related]
8. Preservation of quality of life after intensity-modulated radiotherapy for early-stage nasopharyngeal carcinoma: results of a prospective longitudinal study. McMillan AS; Pow EH; Kwong DL; Wong MC; Sham JS; Leung LH; Leung WK Head Neck; 2006 Aug; 28(8):712-22. PubMed ID: 16475203 [TBL] [Abstract][Full Text] [Related]
9. Intensity modulated radiotherapy for head and neck cancer: evidence for preserved salivary gland function. Saarilahti K; Kouri M; Collan J; Hämäläinen T; Atula T; Joensuu H; Tenhunen M Radiother Oncol; 2005 Mar; 74(3):251-8. PubMed ID: 15763305 [TBL] [Abstract][Full Text] [Related]
10. A phase II study to assess the efficacy of amifostine for submandibular/sublingual salivary sparing during the treatment of head and neck cancer with intensity modulated radiation therapy for parotid salivary sparing. Rosenthal DI; Chambers MS; Weber RS; Eisbruch A Semin Oncol; 2004 Dec; 31(6 Suppl 18):25-8. PubMed ID: 15726519 [TBL] [Abstract][Full Text] [Related]
11. [The relationship between the parotid glands function and the dose-volume effect in nasopharyngeal carcinoma patients with intensity-modulated radiation therapy]. Sun XN; Chen AZ; Xie CY; Jin XC; Wu SX; Zhang P; Li HB Zhonghua Yi Xue Za Zhi; 2006 Aug; 86(32):2289-92. PubMed ID: 17064579 [TBL] [Abstract][Full Text] [Related]
13. Prospective randomized study of intensity-modulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients. Kam MK; Leung SF; Zee B; Chau RM; Suen JJ; Mo F; Lai M; Ho R; Cheung KY; Yu BK; Chiu SK; Choi PH; Teo PM; Kwan WH; Chan AT J Clin Oncol; 2007 Nov; 25(31):4873-9. PubMed ID: 17971582 [TBL] [Abstract][Full Text] [Related]
14. Intensity-modulated radiation treatment for head-and-neck squamous cell carcinoma--the University of Iowa experience. Yao M; Dornfeld KJ; Buatti JM; Skwarchuk M; Tan H; Nguyen T; Wacha J; Bayouth JE; Funk GF; Smith RB; Graham SM; Chang K; Hoffman HT Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):410-21. PubMed ID: 16168834 [TBL] [Abstract][Full Text] [Related]
15. Modeling of salivary production recovery after radiotherapy using mixed models: determination of optimal dose constraint for IMRT planning and construction of convenient tools to predict salivary function. Ortholan C; Chamorey E; Benezery K; Thariat J; Dassonville O; Poissonnet G; Bozec A; Follana P; Peyrade F; Sudaka A; Gerard JP; Bensadoun RJ Int J Radiat Oncol Biol Phys; 2009 Jan; 73(1):178-86. PubMed ID: 18565687 [TBL] [Abstract][Full Text] [Related]
16. Large cohort dose-volume response analysis of parotid gland function after radiotherapy: intensity-modulated versus conventional radiotherapy. Dijkema T; Terhaard CH; Roesink JM; Braam PM; van Gils CH; Moerland MA; Raaijmakers CP Int J Radiat Oncol Biol Phys; 2008 Nov; 72(4):1101-9. PubMed ID: 18472355 [TBL] [Abstract][Full Text] [Related]
17. Phenomenologic model describing flow reduction for parotid gland irradiation with intensity-modulated radiotherapy: evidence of significant recovery effect. Scrimger RA; Stavrev P; Parliament MB; Field C; Thompson H; Stavreva N; Fallone BG Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):178-85. PubMed ID: 15337554 [TBL] [Abstract][Full Text] [Related]
18. Intensity-modulated radiation therapy without concurrent chemotherapy for stage IIb nasopharyngeal cancer. Tham IW; Lin S; Pan J; Han L; Lu JJ; Wee J Am J Clin Oncol; 2010 Jun; 33(3):294-9. PubMed ID: 20395788 [TBL] [Abstract][Full Text] [Related]
19. Dosimetric comparison between 2-dimensional radiation therapy and intensity modulated radiation therapy in treatment of advanced T-stage nasopharyngeal carcinoma: to treat less or more in the planning organ-at-risk volume of the brainstem and spinal cord. Chau RM; Teo PM; Kam MK; Leung SF; Cheung KY; Chan AT Med Dosim; 2007; 32(4):263-70. PubMed ID: 17980826 [TBL] [Abstract][Full Text] [Related]
20. Recurrences after conformal parotid-sparing radiotherapy for head and neck cancer. Bussels B; Maes A; Hermans R; Nuyts S; Weltens C; Van den Bogaert W Radiother Oncol; 2004 Aug; 72(2):119-27. PubMed ID: 15297131 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]